Please login to the form below

Not currently logged in
Email:
Password:

EU approves Janssen's prostate cancer drug

The European Commission has approved Janssen-Cilag's Zytiga, a treatment for metastatic castration-resistant prostate cancer (mCRPC)

Janssen-Cilag has announced that the European Commission (EC) has approved its late stage prostate cancer drug Zytiga (abiraterone acetate) for marketing. The approval follows an accelerated regulatory review process by the European Medicines Agency (EMA) and a positive opinion from the Committee for Medicinal Products for Human Use (CHMP).

Zytiga is a novel, once-daily, oral, androgen biosynthesis inhibitor, which when combined with prednisone or prednisolone, acts as a treatment for metastatic castration-resistant prostate cancer (mCRPC) in adult men whose disease has progressed on or after a docetaxel-based chemotherapy regimen.

Professor Karim Fizazi, Department of Cancer Medicine, Institute Gustave Roussy, France, commented that Zytiga "gives new hope to men who are suffering from this late stage of prostate cancer" and that it helps them "live longer with a better quality of life and less pain."

8th September 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Accession

Accession was a born from a passion and a vision. A passion to harness the power of market access to...

Latest intelligence

Blog: Personality + creatives + sugar = an exciting branding project with the Young Dementia Network
Steve Hunt, Strategy Director for Ashfield Digital & Creative, recently had the opportunity to work on a really exciting and rewarding project with the Young Dementia Network, here he shares...
How merging firms can manage culture change
Addressing the potential problems and finding the solutions...
How to access and engage with HCPs effectively
HCP engagement requires the right mix of voice and content, plus knowledge of the channels to access, to reach the target audience...

Infographics